Evidence map›Paper›PMID 40491603›Full record

ReviewAntibody therapeutics2025

Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors.

Yumei Cheng, Jing Lu, Chonghao Zhang, Weiyuan Yan, Panpan Zhu, Qiuping Qin, Likun Gong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Antibody therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yumei ChengState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.ORCID https://orcid.org/0009-0004-1143-3423
Jing LuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
Chonghao ZhangState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
Weiyuan YanState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
Panpan ZhuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
Qiuping QinState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.
Likun GongState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An antibody-drug conjugate (ADC), consisting of an antibody, a chemical linker, and a payload, can selectively deliver a highly cytotoxic payload to cancer cells and minimize the systemic toxicity of the payload by harnessing the selectivity of the antibody. However, many ADCs have unacceptable toxic effects due to the expression characteristics of target antigens, structural characteristics of antibodies, linker stability and payload properties, which have slowed their development progress. In this review, we describe the effects of the structure of each component of an ADC molecule on its toxicity, explore and discuss the toxicity profiles of various ADCs in the main body tissues/organs by using nonclinical and clinical data obtained from marketed ADCs, aiming to provide a reference for the development of novel ADC molecules and to facilitate related nonclinical and clinical studies.

Indexed as

ADCclinical studynon-clinical studystructural characteristicstoxicity

Identifiers

PMID40491603
PMCPMC12146482

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.